The method described by this Test Guideline provides information that allows hazard assessment for short-term exposure to a test article by inhalation, and allows the substance to be classified according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS). The test method is based on a stepwise procedure, each step using 3 animals of each sex (the preferred species is rat). Animals are exposed in inhalation chambers to a pre-defined concentration for 4 hours. Absence or presence of compound-related mortality of the animals at one step will determine the next step. Animals in severe pain or distress should be humanely killed. The starting concentration is selected from one of four fixed levels corresponding to GHS categories 1-4 for gases, vapours or aerosols. Animals are observed daily for clinical signs of toxicity for a total of at least 14 days. Animals' body weights should be determined at least weekly. All the animals should be subjected to gross necropsy.
Test No. 436: Acute Inhalation Toxicity – Acute Toxic Class Method
Report
Share
Facebook
Twitter
LinkedIn
Abstract
In the same series
-
Report
In Vitro Skin Sensitisation assays addressing the Key Event on activation of dendritic cells on the Adverse Outcome Pathway for Skin Sensitisation
2 July 202694 Pages -
Report
Assays addressing the Adverse Outcome Pathway key event on covalent binding to proteins
2 July 202663 Pages -
Report
Assays addressing the Adverse Outcome Pathway Key Event on Keratinocyte activation
2 July 202698 Pages -
Report
Assay for the Detection of Glucocorticoid Receptor Agonist and Antagonist Activity of Chemicals
2 July 202634 Pages -
2 July 202651 Pages
Related publications
-
2 July 2026115 Pages
-
Report2 July 202632 Pages
-
2 July 202615 Pages
-
Report
Assay for the Detection of Glucocorticoid Receptor Agonist and Antagonist Activity of Chemicals
2 July 202634 Pages -
Report
Assays addressing the Adverse Outcome Pathway key event on covalent binding to proteins
2 July 202663 Pages -
Report
Assays addressing the Adverse Outcome Pathway Key Event on Keratinocyte activation
2 July 202698 Pages